N/A
N=48
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Cervical Dystonia · Blepharospasm
Bottom Line
View on ClinicalTrials.gov: NCT01814774 ↗Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcome: Primary: Dose of Botulinum Toxin Used to Treat Cervical Dystonia — 444.70; 536.30 units per patient per year
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No Intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Jul 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose of Botulinum Toxin Used to Treat Cervical Dystonia |
444.70; 536.30 | — |
| PRIMARY Dose of Botulinum Toxin Used to Treat Blepharospasm |
50.40; 64.01 | — |
| SECONDARY Number of Participants With Adverse Events |
12; 10 | — |
| SECONDARY Botulinum Toxin Inter-injection Interval |
15.83; 14.39 | — |
Summary
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
Eligibility Criteria
Inclusion Criteria
- confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
- treatment with Xeomin® and BOTOX® for at least 1 year each
Exclusion Criteria
- having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
- previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm
Data sourced from ClinicalTrials.gov (NCT01814774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.